iSpecimen

iSpecimen, Inc. operates as healthcare organization that engages in procurement of human biospecimens. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in July 2009 and is headquartered in Lexington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iSpecimen reports improved Q1 performance, eyes growth opportunities ahead

iSpecimen's Q1 2024 earnings call highlighted improved financial performance through cost management and sales growth initiatives.
While facing challenges of lower specimen counts, the company showcased strengths in pricing power, supply efficiency, and cash position.
Opportunities lie in leveraging successful programs, exploring new markets, investing in technology, and strategic partnerships for future growth.
Overall, iSpecimen's positive outlook on operational advancements signals a commitment to sustainable growth and innovation in the healthcare sector.

iSpecimen beats revenue targets, strengthens operations for future growth

iSpecimen delivered strong Q2 2024 results, surpassing revenue targets and improving operational efficiency. The company's strategic initiatives to reduce costs, optimize workforce, and enhance supplier relationships are driving growth. While challenges like funding needs persist, iSpecimen is well-positioned for future opportunities in the healthcare specimen sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

The stock price of iSpecimen Inc (NASDAQ: ISPC) increased by over 4% during intraday trading today. This is why it happened.

iSpecimen Stock (ISPC): Why The Price Went Up Today

ISpecimen Inc (NASDAQ: ISPC) is trading higher Thursday after the company announced the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research. ISpecimen said the reference lab has the capacity to sequence hundreds of COVID-19 positive swabs per week.

Why ISpecimen Shares Are Surging Higher Today

LEXINGTON, Mass., Jan. 13, 2022 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants.

iSpecimen Expands Support of COVID-19 Research with Availability of Sequenced Specimens to Detect Variants

ISPC stock received a $20 price target from Craig-Hallum today. This comes after iSpecimen made several developments during 2021.

ISPC Stock: What Is Going on With Little-Known iSpecimen Today?

Craig-Hallum initiated coverage of iSpecimen Inc (NASDAQ:ISPC) with a Buy rating and $20 price target.  "Much the way Amazon has become the go-to platform for buyers and sellers of consumer goods," the analyst believes iSpecimen can become the go-to platform for human biospecimens, writes analyst Matthew Hewitt.

See why Craig-Hallum Is Bullish On iSpecimen

LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ --  iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in the H.C.

iSpecimen to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

Petros Pharmaceuticals

Longeveron

Reliance Global Group

Vallon Pharmaceuticals

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.

5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List Again

LEXINGTON, Mass., Dec. 16, 2021 /PRNewswire/ -- iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that it has expanded its global supplier network, with 25% of its newest specimen suppliers in 2021 coming from outside the United States.

iSpecimen Expands Global Biospecimen Supplier Network, Broadening Footprint Around the World

Greenland Technologies Holding Corporation

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: GME) and AMC Entertainment Holdings (NYSE: AMC) are two high-profile examples of short-squeezes earlier this year.

5 Short Squeeze Candidates To Watch: Petros Pharma Tops List With 254% Cost To Borrow, One Of Highest Figures On Record

LEXINGTON, Mass., Dec. 2, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced it has recently expanded its global biospecimen provider network in support of research related to neurological disorders, which afflict around one billion people worldwide, or an estimated 1 in 6 people (UN).

iSpecimen Expands Supplier Network of Human Biospecimens to Help Advance Research in Neurological Disorders

LEXINGTON, Mass. , Dec. 1, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that it has closed its previously announced private placement for the sale of 1,749,999 shares of common stock of iSpecimen together with warrants to purchase 1,312,500 shares of common stock ("Warrants"), which resulted in gross proceeds to iSpecimen of approximately $21 million, before deducting offering expenses (the "Offering").

iSpecimen Inc. Announces Closing of Approximately $21 Million Private Placement

The stock price of iSpecimen Inc (NASDAQ: ISPC) increased by over 7% pre-market today. This is why it happened.

iSpecimen (ISPC) Stock: Why The Price Increased Today

The stock price of iSpecimen Inc (NASDAQ: ISPC) fell by over 6% pre-market today. This is why it happened.

iSpecimen (ISPC) Stock: Why The Price Fell Today

LEXINGTON, Mass., Nov. 29, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that it has entered into a definitive securities purchase agreement for a private placement with three accredited investors for the sale of 1,749,999 shares of common stock of iSpecimen together with warrants to purchase 1,312,500 shares of common stock ("Warrants"), which will result in gross proceeds to iSpecimen of approximately $21.0 million, before deducting placement offering expenses.

iSpecimen Inc. Announces $21 Million Private Placement

The stock price of iSpecimen Inc (NASDAQ: ISPC) increased by over 65% pre-market today. This is why it happened.

iSpecimen (ISPC) Stock: Why The Price Surged Today

iSpecimen Inc (NASDAQ: ISPC) is a human biospecimens marketplace that operates online. It announced that private companies and the U.S government had contracted it to be a part of the new advanced Covid-19 research efforts providing the process with human biospecimens.

Here is why iSpecimen is up 50% today

ISpecimen Inc (NASDAQ: ISPC) is trading higher Tuesday on continued upward momentum after the company announced it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes and testing validity among multiple population segments. ISpecimen's work on COVID-19 began immediately after the outbreak last year when it began helping researchers monitor antibody development for possible guidance on immunity.

Why ISpecimen Shares Continue To Move Higher Today

Multiplan Corp

RLX Technology

Why these three penny stocks exploded today The post 3 Hot Penny Stocks to Watch That Exploded Today, One Up 93% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks to Watch That Exploded Today, One Up 93%

iSpecimen (ISPC) stock is up Monday after announcing partnerships with the U.S. Government and private researchers for Covid-19 research. The post ISPC Stock: The Covid-19 Research News That Has iSpecimen Shares Skyrocketing 100% Today appeared first on InvestorPlace.

ISPC Stock: The Covid-19 Research News That Has iSpecimen Shares Skyrocketing 100% Today

iSpecimen Inc (NASDAQ: ISPC), an online marketplace for human biospecimens, has been contracted to support new advanced research on COVID-19.  In the last ten months, the Company has partnered with multiple research and health care organizations on diverse projects requiring a variety of COVID-19 samples, including nasal swabs, saliva, and blood products.

iSpecimen Stock Rallies On Supply Pact Of Human Biospecimens For COVID-19 Research

LEXINGTON, Mass., Nov. 22, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens , today announced that it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments.

iSpecimen Selected by U.S. Government and Private Researchers to Supply Critical Human Biospecimens for Advanced Phase of COVID-19 Research

iSpecimen Inc. (ISPC) CEO Christopher Ianelli on Q3 2021 Results - Earnings Call Transcript

LEXINGTON, Mass., Nov. 4, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today reported its financial results for the three and nine-month periods ended September 30, 2021.

iSpecimen Reports Third Quarter 2021 Financial Results

LEXINGTON, Mass., Nov. 1, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens , today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in two upcoming conferences in November 2021: A.G.P.

iSpecimen to Participate in Upcoming Conferences in November 2021

LEXINGTON, Mass., Oct. 21, 2021 /PRNewswire/ -- iSpecimen Inc.  (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that it will report its financial results for the third quarter ended September 30, 2021, before the market open on Thursday, November 4, 2021.

News for iSpecimen Stock (ISPC)